Table 2:

Markers of Viral Persistence and Inflammation, by Statin Use

	On Statin at A5321 Entry
	Yes (N=72)	No (N=231)	P- Value*
Markers of Viral Persistence
HIV DNA (cps/106 CD4+ T-cells)
Median (Q1 - Q3)	650 (206 - 1,562)	540 (232 - 1,317)	0.58
CA-RNA (cps/106 CD4+ T-cells)
Median (Q1 - Q3)	53 (14 - 198)	37 (14 - 125)	0.12
HIV-1 RNA via iSCA
< 0.4 cps/mL	31 (46%)	120 (54%)	0.27
If ≥0.4 cps/mL
Median (Min - Max)	1.1 (0.4 - 22.0)	1.5 (0.4 - 24.9)
Markers of Inflammation/Immune Activation
IL-6 (pg/mL)
Median (Q1 - Q3)	1.5 (1.1 - 2.0)	1.4 (0.9 - 2.3)	0.20
IP-10 (pg/mL)
Median (Q1 - Q3)	137.2 (93.2 - 183.7)	117.7 (84.3 - 156.3)	0.028
Neopterin (nMol/L)
Median (Q1 - Q3)	9.4 (7.4 - 11.6)	9.1 (7.1 - 10.9)	0.20
sCD14 (ng/mL)
Median (Q1 - Q3)	2,036 (1,548 - 2,444)	1,915 (1,459 - 2,444)	0.41
sCD163 (ng/mL)
Median (Q1 - Q3)	572 (402 - 749)	526 (382 - 776)	0.43
TNF-α (pg/mL)
Median (Q1 - Q3)	1.9 (1.2 - 3.2)	1.9 (1.1 - 3.3)	0.74
CD4+ T-cell activation (% CD38+/HLA-DR+)
	3.5 (2.9 – 4.6)	3.9 (2.9 – 5.5)	0.32
CD8+ T-cell activation (% CD38+/HLA-DR+)
	7.3 (4.4 – 15.1)	9.4 (5.7 – 13.9)	0.22

For markers of viral persistence, the number of participants on statins and not on statins is 68 and 224 for HIV DNA and iSCA; 67 and 216 for CA-RNA. For T-cell activation, the number of participants on statins and not on statins is 24 and 75.

^*Wilcoxon test for continuous variables; Fisher's Exact test for iSCA.

CA-RNA: Cell-associated RNA; iSCA: single copy assay plasma HIV RNA;